New research reveals that people who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end conventional diet and exercise plans.
Research printed in a prominent medical journal points out that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals buying these medications need to be cognizant of the potential of fast rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to starting weight in about a year and a half.
Comparing Treatments
The research, which reviewed dozens of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
Scientists note that individuals who lose weight through lifestyle changes alone generally experience a more gradual weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Doctors suggest the mode of action of the jabs accounts for the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than normal may cause the system to produce less of its endogenous hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication leads to appetite is uncontrolled, making binge eating far more likely."
A Lifelong Condition?
Health authorities recommend the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians say that, due to the high risk of weight regain, the therapy might need to be ongoing.
This opinion is supported by pharmaceutical companies, who note that the results "emphasize the long-term nature of obesity," akin to managing conditions like hypertension.
User Experiences
Individuals who have stopped the jabs explain a sudden return of appetite.
"It was like a trigger flipping and you become extremely hungry," described one woman.
This difficulty is exacerbated if individuals have not established lasting dietary or behavioural modifications during treatment.
Widespread Use
Survey data suggest that a significant number of people in the UK have used weight-loss jabs in the past year, with desire continuing to grow.
- Use is more common among women compared to males.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, experts emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a standalone fix and maintained weight loss hinges on integrated lifestyle management.
